Chronic Adolescent Exposure to Delta-9-Tetrahydrocannabinol in COMT Mutant Mice: Impact on Indices of Dopaminergic, Endocannabinoid and GABAergic Pathways
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Cannabis use confers a two-fold increase in risk for psychosis, with adolescent use conferring an even greater risk. A high-low activity polymorphism in catechol-O-methyltransferase (COMT), a gene encoding the COMT enzyme involved in dopamine clearance in the brain, may interact with adolescent cannabis exposure to increase risk for schizophrenia. The impact of such an interaction on central neurotransmitter pathways implicated in schizophrenia is unknown. Male mice with knockout of the COMT gene were treated chronically with delta-9-tetrahydrocannabinol (THC) during adolescence (postnatal day 32-52). We measured the size and density of GABAergic cells and the protein expression of cannabinoid receptor 1 (CB1R) in the prefrontal cortex (PFC) and hippocampus (HPC) in knockout mice relative to heterozygous mutants and wild-type controls. Size and density of dopaminergic neurons was also assessed in the ventral tegmental area (VTA) across the genotypes. COMT genotype × THC treatment interactions were observed for: (1) dopaminergic cell size in the VTA, (2) CB1R protein expression in the HPC, and (3) parvalbumin (PV) cell size in the PFC. No effects of adolescent THC treatment were observed for PV and dopaminergic cell density across the COMT genotypes. COMT genotype modulates the effects of chronic THC administration during adolescence on indices of neurotransmitter function in the brain. These findings illuminate how COMT deletion and adolescent cannabis use can interact to modulate the function of neurotransmitters systems implicated in schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cannabinoid receptor localization in brain.
Herkenham, M., Lynn, A. B., Little, M. D., Johnson, M. R., Melvin, L. S., de Costa, B. R., & Rice, K. C. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.5.1932 · Cited by 2,321 · cited 3×
“Our GABAergic findings in the COMT mutant mouse are interesting, given that most of the effects of the endocannabinoid system on dopaminergic neurotransmission are GABA- and/or glutamate-mediated (Herkenham et al, 1990; Mailleux and Vanderhaeghen, 1992; Tsou et al, 1998).”
BackgroundCannabis use and risk of psychotic or affective mental health outcomes: a systematic review.
Moore, T. H., Zammit, S., Lingford-Hughes, A., Barnes, T. R., Jones, P. B., Burke, M., & Lewis, G. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61162-3 · Cited by 2,224 · cited 3×
“…is highest when cannabis is consumed during adolescence (Arseneault et al, 2002; Caspi et al, 2005; Konings et al, 2008; McGrath et al, 2010; Moore et al, 2007), possibly because the brain is still developing (Ehrenreich et al, 1999; Pistis et al, 2004; Pope et al, 2003; Schneider and Koch,…”
BackgroundSchizophrenia genes, gene expression, and neuropathology: on the matter of their convergence
Harrison, P. J., & Weinberger, D. R. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001558 · Cited by 2,020
Lachman, H. M., Papolos, D. F., Saito, T., Yu, Y.-M., Szumlanski, C. L., & Weinshilboum, R. M. (1996) · Pharmacogenetics · doi:10.1097/00008571-199606000-00007 · Cited by 1,788
Chen, J., Lipska, B. K., Halim, N., Ma, Q. D., Matsumoto, M., Melhem, S., Kolachana, B. S., Hyde, T. M., Herman, M. M., Apud, J., et al. (2004) · The American Journal of Human Genetics · doi:10.1086/425589 · Cited by 1,675
The principal features and mechanisms of dopamine modulation in the prefrontal cortex
Seamans, J. K., & Yang, C. R. (2004) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2004.05.006 · Cited by 1,592 · cited 7×
“…and cortical dopaminergic activity involving the COMT gene, whereby a narrow range of dopamine can benefit PFC function and either insufficient or excessive dopamine can impair cognitive function (Castner et al, 2000; Goldman-Rakic et al, 2000; Seamans and Yang, 2004; Tunbridge et al, 2006).”
BackgroundInfluentialImmunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system
Tsou, K., Brown, S., Sañudo-Peña, M. C., Mackie, K., & Walker, J. M. (1998) · Neuroscience · doi:10.1016/s0306-4522(97)00436-3 · Cited by 1,586 · cited 3×
“Our GABAergic findings in the COMT mutant mouse are interesting, given that most of the effects of the endocannabinoid system on dopaminergic neurotransmission are GABA- and/or glutamate-mediated (Herkenham et al, 1990; Mailleux and Vanderhaeghen, 1992; Tsou et al, 1998).”
BackgroundThe environment and schizophrenia
van Os, J., Kenis, G., & Rutten, B. P. F. (2010) · Nature · doi:10.1038/nature09563 · Cited by 1,572 · cited 2×
“Reports have shown that a functional polymorphism in the COMT gene can moderate the association between cannabis use and psychosis (Caspi et al, 2005; Harrison and Weinberger, 2005; Tunbridge et al, 2006; van Os et al, 2010), but not all studies support such associations (Zammit et al, 2011).”
BackgroundCaspi, A., Moffitt, T. E., Cannon, M., McClay, J., Murray, R., Harrington, H., Taylor, A., Arseneault, L., Williams, B., Braithwaite, A., et al. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.01.026 · Cited by 1,409
Self-citationCannabis use in adolescence and risk for adult psychosis: longitudinal prospective study.
Arseneault, L., Cannon, M., Poulton, R., Murray, R., Caspi, A., & Moffitt, T. E. (2002) · BMJ · doi:10.1136/bmj.325.7374.1212 · Cited by 1,399 · cited 2×
“…Henquet et al, 2005; Moore et al, 2007), and the risk of developing psychotic symptoms is highest when cannabis is consumed during adolescence (Arseneault et al, 2002; Caspi et al, 2005; Konings et al, 2008; McGrath et al, 2010; Moore et al, 2007), possibly because the brain is still…”
BackgroundSelf-citationLisman, J. E., Coyle, J. T., Green, R. W., Javitt, D. C., Benes, F. M., Heckers, S., & Grace, A. A. (2008) · Trends in Neurosciences · doi:10.1016/j.tins.2008.02.005 · Cited by 1,010 · cited 2×
“Thus, the major neuronal populations modulated by cannabinoids are also ones implicated in schizophrenia (Laviolette and Grace, 2006; Lisman et al, 2008).”
BackgroundHashimoto, T., Volk, D. W., Eggan, S. M., Mirnics, K., Pierri, J. N., Sun, Z., Sampson, A. R., & Lewis, D. A. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-15-06315.2003 · Cited by 938
Gogos, J. A., Morgan, M., Luine, V., Santha, M., Ogawa, S., Pfaff, D., & Karayiorgou, M. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.17.9991 · Cited by 864 · cited 9×
“Áine T Behan*,1, Magdalena Hryniewiecka1, Colm MP O’Tuathaigh2,6, Anthony Kinsella2, Mary Cannon1, Maria Karayiorgou3, Joseph A Gogos4,5, John L Waddington2 and David R Cotter1 1Department of Psychiatry, Royal College of Surgeons in Ireland, Dublin, Ireland; 2Molecular and Cellular Therapeutics, Royal College of Surg…”
BackgroundMethodSelf-citationBilder, R. M., Volavka, J., Lachman, H. M., & Grace, A. A. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300542 · Cited by 769 · cited 5×
“On this basis, we propose that dysregulation of dopaminergic neurons in VTA in schizophrenia (Akil et al, 2003; Bilder et al, 2004) may be exacerbated by adolescent THC-induced, CB1R-mediated, long-term impairment in mesolimbic dopaminergic neuron structure and, hence, signaling.”
BackgroundInfluentialHenquet, C., Krabbendam, L., Spauwen, J., Kaplan, C., Lieb, R., Wittchen, H.-U., & van Os, J. (2005) · BMJ · doi:10.1136/bmj.38267.664086.63 · Cited by 765
Cotter, D. (2002) · Cerebral Cortex · doi:10.1093/cercor/12.4.386 · Cited by 634 · cited 6×
“Recent reports have demonstrated deficits in GABAergic neuronal size and density (Cotter et al, 2002a) to be an indicator of pathophysiological deficits in schizophrenia and to be in line with functional assessments of the same neuronal populations (Hashimoto et al, 2003; Volk et al, 2001).”
BackgroundMethodResultSelf-citationD’Souza, D. C., Abi-Saab, W. M., Madonick, S., Forselius-Bielen, K., Doersch, A., Braley, G., Gueorguieva, R., Cooper, T. B., & Krystal, J. H. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.12.006 · Cited by 617 · cited 2×
“COMT KO mice demonstrated the prominent structural neuronal deficits in this study.”
BackgroundA reduction of nonpyramidal cells in sector CA2 of schizophrenics and manic depressives
Benes, F. M., Kwok, E. W., Vincent, S. L., & Todtenkopf, M. S. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00138-3 · Cited by 470
Cannabinoids Enhance Subsecond Dopamine Release in the Nucleus Accumbens of Awake Rats
Cheer, J. F., Wassum, K. M., Heien, M. L. A. V., Phillips, P. E. M., & Wightman, R. M. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.0529-04.2004 · Cited by 343
Catechol- O -Methyltransferase Genotype and Dopamine Regulation in the Human Brain
Akil, M., Kolachana, B. S., Rothmond, D. A., Hyde, T. M., Weinberger, D. R., & Kleinman, J. E. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-06-02008.2003 · Cited by 325 · cited 8×
“Therefore, our findings of smaller VTA dopaminergic neurons following THC treatment may occur in response to higher cortical CB1R levels in COMT KO mice (Akil et al, 2003).”
BackgroundInfluentialHeckers, S., Stone, D., Walsh, J., Shick, J., Koul, P., & Benes, F. M. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.6.521 · Cited by 322
Hippocampal interneurons are abnormal in schizophrenia
Konradi, C., Yang, C. K., Zimmerman, E. I., Lohmann, K. M., Gresch, P., Pantazopoulos, H., Berretta, S., & Heckers, S. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.06.007 · Cited by 288
Mátyás, F., Urbán, G. M., Watanabe, M., Mackie, K., Zimmer, A., Freund, T. F., & Katona, I. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.05.028 · Cited by 187 · cited 2×
“COMT KO mice demonstrated the prominent structural neuronal deficits in this study.”
BackgroundArnone, D., Barrick, T. R., Chengappa, S., Mackay, C. E., Clark, C. A., & Abou-Saleh, M. T. (2008) · NeuroImage · doi:10.1016/j.neuroimage.2008.02.064 · Cited by 178 · cited 2×
“Studies have shown that heavy cannabis use, especially during adolescence, could contribute to additional changes in global brain structures (Arnone et al, 2008; Matochik et al, 2005; Welch et al, 2011; Wilson and Cadet, 2009; Yucel et al, 2008).”
BackgroundCalcyon upregulation in adolescence impairs response inhibition and working memory in adulthood
Vazdarjanova, A., Bunting, K., Muthusamy, N., & Bergson, C. (2011) · Molecular Psychiatry · doi:10.1038/mp.2011.14 · Cited by 20
Cited by
Brisch, R., Saniotis, A., Wolf, R., Bielau, H., Bernstein, H.-G., Steiner, J., Bogerts, B., Braun, A. K., Jankowski, Z., Kumaritlake, J., et al. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00047 · Cited by 517
The effects of Δ9-tetrahydrocannabinol on the dopamine system
Bloomfield, M. A. P., Ashok, A. H., Volkow, N. D., & Howes, O. D. (2016) · Nature · doi:10.1038/nature20153 · Cited by 373
One Is Not Enough: Understanding and Modeling Polysubstance Use
Crummy, E. A., O’Neal, T. J., Baskin, B. M., & Ferguson, S. M. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00569 · Cited by 351
Adolescent neurodevelopment and substance use: receptor expression and behavioral consequences
Thorpe, H. H. A., Hamidullah, S., Jenkins, B. W., & Khokhar, J. Y. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107431 · Cited by 97
Renard, J., Rushlow, W. J., & Laviolette, S. R. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00281 · Cited by 62
Metadata
- Authors
- Behan, Á. T., Hryniewiecka, M., O'Tuathaigh, C. M. P., Kinsella, A., Cannon, M., Karayiorgou, M., Gogos, J. A., Waddington, J. L., & Cotter, D. R.
- Venue
- Neuropsychopharmacology
- Published
- 2012-03-21
- Volume
- 37
- Issue
- 7
- Pages
- 1773-1783
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W1989764163
- Cited by
- 69
- References
- 25
- FWCI
- 6.40
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.